0126Z0.KS
Samsung Epis Holdings
KOE · Healthcare · Biotechnology · KR
KRW 355,500.00
−2.34%Income statement
| Metric | 2025 |
|---|---|
| Revenue | |
| Total Revenue | 1.0B |
| Cost of Revenue | 112.5M |
| Gross Profit | 61.2M |
| Operating Expenses | |
| R&D Expense | 178.8M |
| SG&A Expense | 442.8M |
| General & Admin Expense | 18.2M |
| Selling & Marketing Expense | 185.6M |
| Other Expenses | (516.5M) |
| Total Operating Expenses | 105.1M |
| Cost and Expenses | 1.3B |
| Operating Income (EBIT) | (244.8M) |
| Non-Operating | |
| Interest Income | 306.4K |
| Interest Expense | 772.4K |
| Net Interest Income | (466.0K) |
| Other Non-Op Income/Expense | 43.7M |
| Non-Operating Income (excl Interest) | — |
| EBT (Pre-Tax Income) | (201.1M) |
| Income Tax Expense | (92.4M) |
| Bottom Line | |
| Net Income | 353.2M |
| Earnings from Cont. Ops | 58.9M |
| Earnings from Discont. Ops | — |
| Bottom Line Net Income | 58.9M |
| Per Share | |
| Basic EPS | ₩14 |
| Diluted EPS | ₩14 |
| Revenue Per Share | ₩42 |
| Shares | |
| Basic Shares Outstanding | 24.9M |
| Diluted Shares Outstanding | 24.9M |
| Profitability Metrics | |
| EBITDA | 18.5M |
| D&A | 282.0M |
| EBIT | (263.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026